All articles by Pradeep Bairaboina
Pradeep Bairaboina
Delpharm to upgrade Boucherville manufacturing facility in Quebec, Canada
The Boucherville plant currently manufactures 20 out of the 100 essential medicines critical to the Canadian healthcare system
OPKO, Entera sign agreement to advance obesity drug candidate
As part of the collaboration, OPKO’s long-acting oxyntomodulin analogue, OPK-88006, will be combined with Entera’s N-Tab technology
Taiho Pharmaceutical to acquire Araris Biotech for up to $1.14bn
Araris Biotech, a spin-off from Switzerland’s Paul Scherrer Institute, specialises in developing next-generation antibody-drug conjugates
Insilico Medicine raises $110m to enhance AI platform and drug pipeline
The proceeds from the financing will be allocated towards advancing Insilico Medicine’s drug development pipeline and improving its AI platform
EC approves Otsuka and Lundbeck’s brexpiprazole to treat adolescent schizophrenia
The EC approval comes after a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, which was issued in January 2025
Salipro Biotech and Boehringer Ingelheim enter research and license agreement to accelerate multiple Boehringer Ingelheim pipeline programs
The collaboration combines Salipro Biotech’s unique expertise and its Salipro platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable and accelerate the development of novel therapeutics
AstraZeneca receives EC approval for Tagrisso in non-small cell lung cancer
The EC approval follows a positive opinion from the Committee for Medicinal Products for Human Use and is based on findings from the LAURA Phase III trial
AbbVie to acquire Nimble Therapeutics in $200m deal
The deal will provide AbbVie access to Nimble’s proprietary peptide synthesis platform, which facilitates the discovery and optimisation of oral peptide therapeutics.
Catalent and Novo Holdings to finalise acquisition following regulatory clearance
The agreement, initially announced in February, involves Novo Holdings acquiring Catalent and Novo Nordisk purchasing three fill-finish manufacturing sites from Catalent for $11bn